Markers of early vascular aging are not associated with cryptogenic ischemic stroke in the young: A case-control study

Lisätietoja

Funding Information:
Helsinki and Uusimaa Hospital District research fund (TYH2014407, TYH2018318); Academy of Finland (286246, 318075, 322656); Doctoral School in Health Sciences, University of Helsinki, and Sahlgrenska University Hospital. D.G. was supported by Academy of Finland (1219001), University of Helsinki (Clinical Researcher stint), Wilhelm and Else Stockmann Foundation, Finska Läkaresällskapet (Medical Society of Finland), Liv och Hälsa Society, Sigrid Juselius Foundation, Päivikki and Sakari Sohlberg Foundation, and Perklén Foundation.

Funding Information:
Helsinki and Uusimaa Hospital District research fund ( TYH2014407 , TYH2018318 ); Academy of Finland ( 286246 , 318075 , 322656 ); Doctoral School in Health Sciences, University of Helsinki, and Sahlgrenska University Hospital. D.G. was supported by Academy of Finland ( 1219001 ), University of Helsinki (Clinical Researcher stint), Wilhelm and Else Stockmann Foundation, Finska Läkaresällskapet (Medical Society of Finland), Liv och Hälsa Society, Sigrid Juselius Foundation, Päivikki and Sakari Sohlberg Foundation, and Perklén Foundation.

Funding Information:
D.G. has received lecture or advisory honoraria from AstraZeneca, Boehringer Ingelheim, Fresenius, GE Healthcare, and Novo Nordisk, and support to attend medical meetings from CVRx and Sanofi Aventis, T.T.: Academic grants from European Union, Finnish Academy of Sciences, University of Gothenburg, Sahlgrenska University Hospital, Sigrid Juselius Foundation, and Wennerström's Foundation. Research contracts with Bayer, Boehringer Ingelheim, and Bristol Myers Squibb. Advisory board memberships: Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Portola Pharm. Other authors report no conflicts of interest.

Publisher Copyright:
© 2022 The Author(s)